IL165690A0 - Novel crystalline forms of gatifloxacin - Google Patents

Novel crystalline forms of gatifloxacin

Info

Publication number
IL165690A0
IL165690A0 IL16569004A IL16569004A IL165690A0 IL 165690 A0 IL165690 A0 IL 165690A0 IL 16569004 A IL16569004 A IL 16569004A IL 16569004 A IL16569004 A IL 16569004A IL 165690 A0 IL165690 A0 IL 165690A0
Authority
IL
Israel
Prior art keywords
gatifloxacin
crystalline forms
novel crystalline
novel
forms
Prior art date
Application number
IL16569004A
Other languages
English (en)
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IL165690A0 publication Critical patent/IL165690A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL16569004A 2002-06-14 2004-12-09 Novel crystalline forms of gatifloxacin IL165690A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38909302P 2002-06-14 2002-06-14
US42333802P 2002-11-01 2002-11-01
PCT/US2003/019046 WO2003105851A1 (en) 2002-06-01 2003-06-16 Novel crystalline forms of gatifloxacin

Publications (1)

Publication Number Publication Date
IL165690A0 true IL165690A0 (en) 2006-01-15

Family

ID=29740100

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16569004A IL165690A0 (en) 2002-06-14 2004-12-09 Novel crystalline forms of gatifloxacin

Country Status (8)

Country Link
US (2) US7411067B2 (zh)
EP (1) EP1471911A1 (zh)
JP (1) JP2005532364A (zh)
CN (1) CN1674902A (zh)
AU (1) AU2003243615A1 (zh)
CA (1) CA2489377A1 (zh)
IL (1) IL165690A0 (zh)
WO (1) WO2003105851A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118546A1 (en) * 2004-06-04 2005-12-15 Matrix Laboratories Ltd Novel crystalline forms of gatifloxacin
CA2621616A1 (en) * 2007-02-19 2008-08-19 Alcon Research, Ltd. Topical gatifloxacin formulations
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 ｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69331003T2 (de) 1992-01-31 2002-06-20 Chugai Seiyaku K.K., Tokio/Tokyo Kristalle von derivaten von chinozon carbonsäure-hydraten
JP3449658B2 (ja) 1994-12-21 2003-09-22 杏林製薬株式会社 安定性に優れた８−アルコキシキノロンカルボン酸水和物並びにその製造方法
US6413969B1 (en) 2000-09-13 2002-07-02 Bristol-Myers Squibb Company Gatifloxacin pentahydrate
EP1492535B1 (en) 2002-04-08 2005-10-26 Dr. Reddy's Laboratories Ltd. Anhydrous crystalline forms i and ii of 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl) 4-oxo-1, 4-dihydroquinoline-3-carboxylic acid (gatifloxacin)

Also Published As

Publication number Publication date
US7411067B2 (en) 2008-08-12
US20040038988A1 (en) 2004-02-26
CN1674902A (zh) 2005-09-28
CA2489377A1 (en) 2003-12-24
AU2003243615A1 (en) 2003-12-31
US20080269488A1 (en) 2008-10-30
WO2003105851A1 (en) 2003-12-24
EP1471911A1 (en) 2004-11-03
JP2005532364A (ja) 2005-10-27

Similar Documents

Publication Publication Date Title
AU2003230192A1 (en) Novel crystalline forms of aripiprazole
ZA200409981B (en) Novel formate salt of O-desmethyl-venlafaxine
HK1103294A1 (en) Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride (6r)-l--
ZA200507344B (en) Novel crystalline modification of the anhydrate of boscalid
IL172006A0 (en) Novel crystalline forms of valacyclovir hydrochloride
IL166592A0 (en) Novel crystalline forms of gatifloxacin
IL165115A0 (en) Novel crystalline forms of gatifloxacin
AU2003245029A1 (en) Novel crystalline forms of donepezil hydrochloride
AU2003297594A8 (en) Crystalline form
AU2003245027A1 (en) Novel crystalline forms of ziprasidone hydrochloride
AU2003232719A1 (en) Novel crystalline forms of valacyclovir hydrochloride
AU2003295638A8 (en) Novel inhibitors of beta-lactamase
IL165690A0 (en) Novel crystalline forms of gatifloxacin
IL174969A0 (en) Crystalline forms of (+)-and (-) erythro-mefloquine hydrochloride
AU2003217438A1 (en) Novel crystalline forms of levetiracetam
AU2003298725A8 (en) Preparation of metallotexaphyrins
PL375437A1 (en) Synthesis of gatifloxacin
AU2003300874A1 (en) Crystalline forms of gatifloxacin and processes for preparation
AU2003217437A1 (en) Novel crystalline forms of lamotrigine
EP1486485A4 (en) NEW 5-HYDROXYCARBAMIMIDOYL-2-HYDROXYBENZENESULFONAMIDE DERIVATIVE CRYSTALS
AU2003230194A1 (en) Novel crystalline forms of gatifloxacin
IL174063A0 (en) Crystalline form of gatifloxacin
AU2003238668A1 (en) Novel crystalline forms of valdecoxib
AU2003209670A1 (en) Novel crystalline forms of trandolapril
GB0228533D0 (en) Crystalline form